Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.10.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 12 Months Ended
Sep. 30, 2018
Sep. 30, 2017
REVENUES    
Total revenues $ 1,315,500 $ 128,500
Cost of revenues 827,400 53,500
Gross Margin 488,100 75,000
OPERATING EXPENSES    
Research 231,500 123,900
Product development 1,146,000 1,237,200
Sales and marketing 1,617,900 1,226,700
General and administrative 7,737,600 4,590,800
Total operating expenses 10,733,000 7,178,600
OPERATING LOSS (10,244,900) (7,103,600)
OTHER INCOME (EXPENSE):    
Interest expense, net (86,300) (6,600)
Total other income (expense) (86,300) (6,600)
LOSS BEFORE PROVISION FOR INCOME TAXES (10,331,200) (7,110,200)
Provision for income taxes 1,900 2,600
NET LOSS (10,333,100) (7,112,800)
Net loss attributable to noncontrolling interest (734,400)
Net Loss attributable to MYnd Analytics, Inc. $ (9,598,700) $ (7,112,800)
BASIC AND DILUTED LOSS PER SHARE (in dollars per share) $ (1.86) $ (2.52)
WEIGHTED AVERAGE SHARES OUTSTANDING:    
Basic and Diluted (in shares) 5,199,566 2,817,415
Neurometric Services [Member]    
REVENUES    
Total revenues $ 263,700 $ 128,500
Cost of revenues 131,200 53,500
Telepsychiatry Services [Member]    
REVENUES    
Total revenues 1,051,800
Cost of revenues $ 696,200